| Weight | 1 lbs |
|---|---|
| Dimensions | 9 × 5 × 2 in |
| target | Borrelia burgdorferi reactive IgM |
| species reactivity | Borrelia burgdorferi |
| applications | ELISA |
| assay type | Indirect & quantitative |
| available size | 3 mL |
Borrelia burgdorferi IgM Control Serum BC121M
$94.00
Summary
- Virion/Serion Diagnostic Kit Control for research use (RUO)
- Borrelia burgdorferi IgM Control Serum
- Applications: ELISA
- IgM control serum
- Ready-to-use; pre-diluted for SERION ELISA classic and SERION ELISA antigen assays
- 3 mL
Borrelia burgdorferi IgM Control Serum BC121M
| target relevance |
|---|
| Organism Borrelia burgdorferi |
| Structure and strains Borrelia burgdorferi is a bacterial species of the spirochete class in the genus Borrelia, and is one of the causative agents of Lyme disease in humans. Along with a few similar genospecies, some of which also cause Lyme disease, it makes up the species complex of Borrelia burgdorferi sensu lato. The complex currently comprises 20 accepted and 3 proposed genospecies.B. burgdorferi sensu stricto exists in North America and Eurasia and until 2016 was the only known cause of Lyme disease in North America. Borrelia species are Gram-negative. |
| Disease Pathogens Borrelia burgdorferi is the infectious agent of Lyme-Borreliosis. B. burgdorferi sensu stricto, B. garinii, B. afzelii and B. spielmanii are the most important human pathogens of the genospecies Borrelia burgdorferi sensu lato. All four species are distributed throughout Europe in temperate climate zones. Reservoirs for the bacteria include a variety of mammals, particularly mice. The bacteria are transmitted to human hosts by infected ticks. Lyme-Borreliosis is a multisystemic disease. Dermal manifestations with Erythema migrans (EM) as a characteristic symptom of early disease are displayed by 70 to 90 % of infected persons. In addition to non-specific symptoms, in particular neurological disorders, e. g. Morbus Bannwarth, may be observed between a few weeks and several months post infection as signs of a systemic disease with single or multiple organ involvement. Development of late-stage symptoms may occur up to several years after the tick bite and are characterized by dermatological diseases (Acrodermatitis chronica athrophicans), diseases of the joints (Lyme-Arthritis), and neurological diseases (chronical encephalomyelitis). |
| Detection and diagnosis Due to the complexity of the clinical picture and the generally unspecific symptoms, serology is the appropriate method to ensure an optimal diagnosis. It is recommended to adopt a logical step-wise approach for serological diagnosis, initially using a sensitive screening assay with subsequent confirmation by another specific test. |
Data
Publications
Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.| pmid | title | authors | citation |
|---|
Protocols
| relevant to this product |
|---|
| BC121M protocol |
Documents
| # | ||
|---|---|---|
| No results found | ||
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.